Lilly names former Genentech exec as VP oncology research; Sanofi-Aventis names SDSAC chairman

11 March 2011

US drug major Eli Lilly (NYSE: LLY) has recruited former Genentech executive Greg Plowman to lead its oncology research efforts as the vice president, oncology research and senior vice president of ImClone Systems research.

In this innovative new role created by Lilly and ImClone, which was acquired in 2008, Dr Plowman will oversee the oncology research efforts of both Lilly and its subsidiary. He will be based at ImClone's research center at the Alexandria Center for Life Science - New York City and will start on March 28. He will report jointly to Jan Lundberg, executive vice president, science and technology, and president, Lilly Research Laboratories (LRL), and Bernhard Ehmer, president of ImClone.

Oncology Research at Lilly, ImClone

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK